XSNX
NovAccess Global Inc. [XSNX] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
XSNX Stock Summary
In the News
XSNX Financial details
Company Rating
Neutral
Market Cap
283.65K
Income
-789.95K
Revenue
0
Book val./share
-0.28
Cash/share
0
Dividend
-
Dividend %
-
Employees
3
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-0.4
Forward P/E
-
PEG
0.02
P/S
-
P/B
-0.07
P/C
-
P/FCF
-0.66
Quick Ratio
0.02
Current Ratio
0.03
Debt / Equity
-0.34
LT Debt / Equity
-
-
-
EPS (TTM)
-0.04
EPS next Y
-
EPS next Q
-
EPS this Y
-742.46%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
-168.63%
-
-
-
-
SMA20
-
SMA50
-50%
SMA100
-66.67%
Inst Own
0%
Inst Trans
0%
ROA
-615%
ROE
18%
ROC
0.38%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.0081-0.22
52W High
-
52W Low
-
RSI
40.49
Rel Volume
0.34
Avg Volume
355.07K
Volume
121.13K
Perf Week
-32.96%
Perf Month
-46.76%
Perf Quarter
-84.92%
Perf Half Y
-85.86%
-
-
-
-
Beta
1.458
-
-
Volatility
0%, 0%
Prev Close
11.73%
Price
0.00905
Change
-4.74%
XSNX Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-09-30
| Metric | History | 2019-09-30 | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 1.03K | 0 | 0 | 0 | 0 | |
| Net income per share | 1.5K | -4.24 | -0.26 | 0.04 | -0.23 | |
| Operating cash flow per share | -4.19 | -0.06 | -0.06 | -0.05 | -0.03 | |
| Free cash flow per share | -5.66 | -0.06 | -0.06 | -0.05 | -0.03 | |
| Cash per share | 5.11 | 0 | 0.02 | 0 | 0 | |
| Book value per share | -1.43K | -2.23 | -0.35 | -0.28 | -0.37 | |
| Tangible book value per share | -1.43K | -2.23 | -0.35 | -0.28 | -0.37 | |
| Share holders equity per share | -1.43K | -2.23 | -0.35 | -0.28 | -0.37 | |
| Interest debt per share | 188.06 | 0.17 | 0.06 | 0.18 | 0.16 | |
| Market cap | 779.74 | 1.12M | 5.23M | 1.98M | 2.08M | |
| Enterprise value | 214.11K | 1.37M | 5.35M | 3.21M | 4.26M | |
| P/E ratio | 0 | -0.17 | -1.81 | 3.35 | -0.44 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -0.12 | -12.04 | -7.66 | -2.19 | -3.33 | |
| PFCF ratio | -0.09 | -12.04 | -7.66 | -2.19 | -3.33 | |
| P/B Ratio | 0 | -0.31 | -1.33 | -0.43 | -0.27 | |
| PTB ratio | 0 | -0.31 | -1.33 | -0.43 | -0.27 | |
| EV to sales | 0.13 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | 1.03 | -0.23 | -2 | -1.38 | -1.73 | |
| EV to operating cash flow | -32.73 | -14.65 | -7.85 | -3.55 | -6.82 | |
| EV to free cash flow | -24.26 | -14.65 | -7.85 | -3.55 | -6.82 | |
| Earnings yield | 3.01K | -6.06 | -0.55 | 0.3 | -2.27 | |
| Free cash flow yield | -11.32 | -0.08 | -0.13 | -0.46 | -0.3 | |
| Debt to equity | -0.1 | -0.07 | -0.08 | -0.28 | -0.28 | |
| Debt to assets | 1.03 | 1.37K | 1.48 | 10.32 | 35.34 | |
| Net debt to EBITDA | 1.03 | -0.04 | -0.05 | -0.53 | -0.88 | |
| Current ratio | 0.09 | 0 | 0.05 | 0.03 | 0.01 | |
| Interest coverage | 2.88 | -27.14 | -7.14 | -0.81 | -2.02 | |
| Income quality | 0 | 0.01 | 0.27 | 0.53 | 0.13 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 39.61K | |
| Payout ratio | 0 | 0 | 0 | 0 | -17.46K | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.35 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -3.94 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 6.96K | 14.58 | 1.42 | 0.48 | 1.38 | |
| ROIC | -0.1 | 0.24 | 0.86 | -0.14 | 0.44 | |
| Return on tangible assets | 10.89 | -38.21K | -13.89 | 4.73 | -75.91 | |
| Graham Net | -1.47K | -2.23 | -0.35 | -0.29 | -0.38 | |
| Working capital | -2.07M | -3.45M | -3.76M | -4.65M | -7.8M | |
| Tangible asset value | -2.24M | -3.57M | -3.93M | -4.65M | -7.8M | |
| Net current asset value | -2.24M | -3.57M | -3.93M | -4.65M | -7.8M | |
| Invested capital | -0.1 | -0.07 | -0.08 | -0.28 | -0.28 | |
| Average receivables | 152.45K | 99.04K | 190 | 190 | 0 | |
| Average payables | 131.91K | 108.97K | 115.8K | 259.38K | 445.18K | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 44.94 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 55.18 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 8.12 | 0 | 0 | 0 | 0 | |
| Payables turnover | 6.62 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -1.05 | 1.91 | 0.74 | -0.13 | 0.61 | |
| Capex per share | -1.46 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q1
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.14 | 0.02 | -0.04 | -0.08 | 0.06 | |
| Operating cash flow per share | -0.01 | -0.01 | -0.01 | -0.01 | 0 | |
| Free cash flow per share | -0.01 | -0.01 | -0.01 | -0.01 | 0 | |
| Cash per share | 0 | 0 | 0 | 0 | 0 | |
| Book value per share | -0.37 | -0.28 | -0.29 | -0.36 | -0.28 | |
| Tangible book value per share | -0.37 | -0.28 | -0.29 | -0.36 | -0.28 | |
| Share holders equity per share | -0.37 | -0.28 | -0.29 | -0.36 | -0.28 | |
| Interest debt per share | 0.1 | 0.11 | 0.11 | 0.12 | 0.1 | |
| Market cap | 5.5M | 3.62M | 2.33M | 2.17M | 468.62K | |
| Enterprise value | 7M | 5.38M | 4.18M | 4.35M | 2.65M | |
| P/E ratio | -0.52 | 2 | -0.75 | -0.31 | 0.09 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -34.55 | -18.37 | -20.6 | -14.04 | -11.74 | |
| PFCF ratio | -34.55 | -18.37 | -20.6 | -14.04 | -11.74 | |
| P/B Ratio | -0.78 | -0.63 | -0.37 | -0.28 | -0.07 | |
| PTB ratio | -0.78 | -0.63 | -0.37 | -0.28 | -0.07 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -13.55 | -5.1 | -8.62 | -10.11 | -10.31 | |
| EV to operating cash flow | -43.97 | -27.28 | -36.9 | -28.11 | -66.51 | |
| EV to free cash flow | -43.97 | -27.28 | -36.9 | -28.11 | -66.51 | |
| Earnings yield | -0.48 | 0.13 | -0.33 | -0.81 | 2.78 | |
| Free cash flow yield | -0.03 | -0.05 | -0.05 | -0.07 | -0.09 | |
| Debt to equity | -0.22 | -0.31 | -0.31 | -0.28 | -0.34 | |
| Debt to assets | 26.29 | 17.19 | 10.78 | 35.34 | 126.16 | |
| Net debt to EBITDA | -2.9 | -1.67 | -3.81 | -5.06 | -8.49 | |
| Current ratio | 0.01 | 0.02 | 0.03 | 0.01 | 0 | |
| Interest coverage | -1.72 | -2.31 | -1.13 | -1.12 | -3.59 | |
| Income quality | 0.06 | -0.43 | 0.15 | 0.09 | -0.03 | |
| Dividend Yield | 0 | 0 | 0 | 37.94K | 0 | |
| Payout ratio | 0 | 0 | 0 | -46.67K | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 1.07 | 0.37 | 0.49 | 0.81 | 0.59 | |
| ROIC | 0.09 | 0.27 | 0.11 | 0.09 | 0.06 | |
| Return on tangible assets | -44.95 | 4.39 | -4.4 | -28.4 | 75.19 | |
| Graham Net | -0.37 | -0.28 | -0.3 | -0.36 | -0.28 | |
| Working capital | -7.03M | -5.73M | -6.23M | -7.8M | -6.43M | |
| Tangible asset value | -7.03M | -5.73M | -6.23M | -7.8M | -6.43M | |
| Net current asset value | -7.03M | -5.73M | -6.23M | -7.8M | -6.43M | |
| Invested capital | -0.22 | -0.31 | -0.31 | -0.28 | -0.34 | |
| Average receivables | 0 | 0 | 32.99K | 32.99K | 0 | |
| Average payables | 409.54K | 445.12K | 483.59K | 517.52K | 552.61K | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 0.37 | -0.08 | 0.13 | 0.23 | -0.2 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
XSNX Frequently Asked Questions
What is NovAccess Global Inc. stock symbol ?
NovAccess Global Inc. is a US stock , located in Chesterland of Oh and trading under the symbol XSNX
What is NovAccess Global Inc. stock quote today ?
NovAccess Global Inc. stock price is $0.00905 today.
Is NovAccess Global Inc. stock public?
Yes, NovAccess Global Inc. is a publicly traded company.
Company Profile
- Volume Average 355.07K
- Market Capitalization 283.65K
- Employee 3
- CEO Dr. Dwain K. Morris-Irvin M.P.H., MPH, Ph.D.
- Headquarters Chesterland,OH,US
- IPO Date 1998-09-21
-
Website
https://novaccessglobal.com 
NovAccess Global Inc., a biopharmaceutical company, develops novel immunotherapies to treat brain tumor patients in the United States. The company specializes in cutting-edge research related to utilizing a patient's immune system to attack the cancer. NovAccess Global Inc. was incorporated in 1997 and is headquartered in Chesterland, Ohio.
